Brief: Homology Medicines Inc Currently Estimates That It Will Incur Approximately $6.8 Million In Charges In Connection With Reduction In Force
July 27 (Reuters) - Homology Medicines Inc FIXX.O :
* HOMOLOGY MEDICINES INC - CURRENTLY ESTIMATES THAT IT WILL
INCUR
APPROXIMATELY $6.8 MILLION IN CHARGES IN CONNECTION WITH
REDUCTION IN FORCE
* HOMOLOGY MEDICINES INC - EXPECTS THAT MAJORITY OF CHARGES
RELATED TO REDUCTION IN FORCE WILL BE INCURRED IN Q3 OF 2023
Further company coverage: FIXX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Q32 Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview